Detection of human papillomavirus by the polymerase chain reaction using specific L1, and E6 probes

• US 5,705,627 A
• Filed: 05/26/1995
• Issued: 01/06/1998
• Est. Priority Date: 09/09/1988
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Roche Molecular Systems (Roche Holding AG)
• Inventors: Greer, Catherine E., Resnick, Robert M., Bauer, Heidi M., Ting, Yi, Manos, M. Michele
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): FREDMAN, JEFFREY NORMAN
• Application Number:
  US08/452,055
• Time in Patent Office: 956 Days
• Field of Search: 435/6, 435/91.2, 536/22.1, 536/23.1, 536/24.3, 536/24.31, 536/24.32, 536/24.33, 536/24.5
• US Class Current: 536/24.3
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

The presence of human papillomavirus (HPV) in a sample can be detected and the HPV typed by a method that involves the amplification of HPV DNA sequences by the polymerase chain reaction (PCR). The primers used in the method are consensus primers that can be used to amplify a particular region of the genome of any HPV. The presence of HPV in a sample is indicated by the formation of amplified DNA. The HPV nucleic acid is detected by consensus probes that may be short oligonucleotide probes or long generic probes. The HPV is typed by the use of type-specific DNA probes specific for the amplified region of DNA.

Claims

1. An HPV L1 type-specific probe selected from the group consisting of:

MY12, MY13, MY14, MY16, MY58, MY59, MY60, MY61, MY62, MY63, MY64, MY65, MY71 (Seq ID No.

     12), MY72 (Seq ID No.

     13), MY73 (Seq ID No.

     18), MY83 (Seq ID No.

     68), MY84 (Seq ID No.

     84), MY85 (Seq ID No.

     71), MY86 (Seq ID No.

     70), MY95 (Seq ID No.

     14), MY96 (Seq ID No.

     15), MY97 (Seq ID No.

     16), MY104 (Seq ID No.

     74), MY105 (Seq ID No.

     75), MY106 (Seq ID No.

     76), MY107 (Seq ID No.

     19), MY125 (Seq ID No.

     10), MY126 (Seq ID No.

     11), MY130 (Seq ID No.

     20), MY131 (Seq ID No.

     21), MY132 (Seq ID No.

     22), MY133 (Seq ID No.

     17), WD74, WD75 (Seq ID No.

     23), WD150, WD151, and sequences fully complementary thereto.

2. An HPV L1 region primer selected from the group consisting of MY09, MY11, MY74, MY75, MY76, MY77, MY47, MY48, MY49, and MY50.

3. An HPV L1 region consensus probe selected from the group consisting of WD147, MY46, and sequences fully complementary thereto.

4. An HPV E6 region consensus probe selected from the group consisting of WD135, WD136, MY135, MY136, WD83, WD84, WD64, WD65, and sequences fully complementary thereto.

5. An HPV E6 region type-specific probe selected from the group consisting of WD170, RR1, RR2, WD132, WD104, WD102, WD103, WD133, WD134, WD78, WD79, WD80, WD81, WD82, and sequences fully complementary thereto.

6. A pair of consensus HPV primers, wherein said consensus HPV primers consists of positive and negative strand primers and said positive primers are selected from the group consisting of:

WD72/WD73, WD72/WD76, WD72/WD77, WD65/WD64, WD83/WD64, and WD84/WD64; and

said negative strand primers are selected from the group consisting of WD70/WD71;

WD68/WD69; and

WD66/WD67.

7. A pair of consensus HPV primers wherein said consensus HPV primer pair consists of MY09 and MY11.

8. A pair of consensus HPV primers consisting of oligonucleotides selected from the group consisting of:

WD64/WD65 and TYN01/TYN02/TYN03;

WD64/WD65 and TYN04/TYN05/TYN06;

WD64/WD65 and TYN07/TYN08;

WD72/WD76 and TYN01/TYN02/TYN03;

WD72/WD76 and TYN04/TYN05/TYN06;

WD72/WD76 and TYN07/TYN08;

TYP01/TYP02/TYPO3 and TYN07/TYN08; and

TYP04/TYP05/TYP06 and TYN07/TYN08.